Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Articles|December 21, 2021
Daily OTC Pearl: Terrasil Shingles Skincare
Author(s)Saro Arakelians, PharmD
Terrasil Shingles Skincare helps to alleviate pain, itching, burning, and irritation associated with shingles.
Advertisement
OTC/Lifestyle Pearl of the Day: Terrasil Shingles Skincare
Indication: The Terrasil Shingles Skincare formula soothes, cools, and calms irritated, painful shingles rashes to help alleviate patients’ symptoms at a more rapid rate.
Insight:
- The Terrasil Shingles Skincare has a triple action formula that alleviate patients’ symptoms faster than shingles creams that work to address a singular aspect of patients’ symptoms.
- Terrasil Shingles Skincare is designed for people with sensitive skin that has been aggravated by shingles.
- Ingredients in Terrasil Shingles Skincareincludecotton seed oil, beeswax (organic), vegetable stearic acid (naturally sourced), jojoba seed oil, bentonite (volcanic clay), peppermint oil, silver oxide, magnesium oxide, and zinc oxide.
- Cautions when using Terrasil Shingles Skincareincludemaking sure toavoid any contact with the eyes. If contact occurs, eyes should be rinsed thoroughly with water.
- Terrasil Shingles Skincare is a topical ointment for the management of pain, itching, burning, and irritation associated with shingles.
- Terrasil Shingles Skincare is an OTC treatment for managing shingles symptoms that appear alongside a shingles rash, which is caused by the herpes zoster virus.
Source:
Advertisement
Related to this article
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5